Deresiewicz R L, Austin P R, Hovde C J
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
Mol Gen Genet. 1993 Nov;241(3-4):467-73. doi: 10.1007/BF00284701.
Shiga-like toxin I (SLT-I), the potent cytotoxin produced by certain pathogenic strains of Escherichia coli, is a member of a burgeoning family of ribosome-in-activating proteins (RIPs), which share common structural and mechanistic features. The prototype of the group is the plant toxin ricin. Recently we proposed a structural model for the Slt-IA active site, based in part on the known geometry of the enzymatic subunit of the ricin toxin. The model places three aromatic residues within the putative Slt-IA active site cleft: tyrosine 77, tyrosine 114, and tryptophan 203. Here we present biochemical and biophysical data regarding, the phenotypes of conservative point mutants of Slt-IA in which tyrosine 114 is altered. We used oligonucleotide-directed mutagenesis to replace tyrosine 114 with either phenylalanine (Y114F) or serine (Y114S). Periplasmic extracts of E. coli containing wild-type or mutant Slt-IA were tested for their ability to inhibit protein synthesis in vitro. Relative to wild-type, the activity of mutant Y114F was attenuated about 30-fold, while the mutant Y114S was attenuated about 500 to 1000-fold. In order to address the possibility that differential activation of the mutants rather than local effects at the active site might account for their diminished activity, we engineered the same mutations into a truncated slt-IA cassette that directs expression of a product corresponding to the activated A1 form of Slt-IA (wild-type-delta). The same general relationships held: relative to wild type-delta, Y114F-delta was attenuated about 7-fold, and Y114S-delta about 300-fold.(ABSTRACT TRUNCATED AT 250 WORDS)
志贺样毒素I(SLT-I)是由某些致病性大肠杆菌菌株产生的强效细胞毒素,是一个新兴的核糖体失活蛋白(RIPs)家族的成员,这些蛋白具有共同的结构和作用机制。该家族的原型是植物毒素蓖麻毒素。最近,我们基于蓖麻毒素酶亚基的已知几何结构,提出了Slt-IA活性位点的结构模型。该模型在假定的Slt-IA活性位点裂隙内放置了三个芳香族残基:酪氨酸77、酪氨酸114和色氨酸203。在此,我们展示了关于Slt-IA保守点突变体表型的生化和生物物理数据,其中酪氨酸114发生了改变。我们使用寡核苷酸定向诱变将酪氨酸114替换为苯丙氨酸(Y114F)或丝氨酸(Y114S)。测试了含有野生型或突变型Slt-IA的大肠杆菌周质提取物在体外抑制蛋白质合成的能力。相对于野生型,突变体Y114F的活性减弱了约30倍,而突变体Y114S减弱了约500至1000倍。为了解决突变体的差异激活而非活性位点的局部效应可能导致其活性降低的可能性,我们将相同的突变引入到一个截短的slt-IA盒中,该盒指导表达与激活的Slt-IA A1形式(野生型-δ)相对应的产物。相同的一般关系成立:相对于野生型-δ,Y114F-δ减弱了约7倍,Y114S-δ减弱了约300倍。(摘要截短至250字)